Infectious Disease Advisor news story
Among adults with HIV-1 and prior hepatitis B virus (HBV) exposure, treatment with dolutegravir plus lamivudine (DTG/3TC) is associated with high rates of virologic suppression without evidence of HBV reactivation, according to study findings published in HIV Medicine.
To better characterize the safety of tenofovir-sparing antiretroviral therapy regimens in patients at risk for HBV reactivation and to evaluate virologic suppression outcomes in those with isolated reactive hepatitis B core antibodies (anti-HBc), investigators conducted a secondary pooled analysis of data from 5 phase 3/3b studies: GEMINI-1 and GEMINI-2, STAT, TANGO, and SALSA.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
-
[Report] ECDC: 59 000 deaths: Europe off track for SDG targets for HIV, TB, viral hepatitis, and STIs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.